The University of Rochester Clinical and Translational Science Institute (UR CTSI) will be created as the academic home for clinical and translational science, providing a centralized, integrated infrastructure. Under a systemof governance in which the UR CTSI Program Director has authority over space, faculty, budgets, and other resources related to the CTSI, and in which much of the current GCRC budget is distributed to CTSI Key Functions in support of these functions, we plan to transformthe two distinct research fields of clinical and translational science into a single new discipline. The goals of this discipline nclude the creation of new knowledgeand techniques to diagnose, prevent and treat human disease, and he establishment of an environment that catalyzes their application to clinical practice in the community. To achieve these goals, we propose specific aims involving: novel methodologies;pilot studies;upgraded biomedical informatics, epidemiology, research design, ethics, and regulatory support;community engagement;new technology and resourcecores;new educational and training programs;an UpstateNew York Consortium;and rigorous evaluation and measurement of performanceoutcomes. Strategic planning for the UR CTSI has been underway for several years prior to this RFA. Evidence of institutional support includes commitment to a new 150,000 sq. ft. Clinical and Translational Science Building (CTSB) in which faculty conducting clinical and translational researchwill be brought together with students and trainees in existing and new degree-granting programs,with supporting regulatory and administrative functions, and with facultyworking in collaborative disciplines such as biostatistics, epidemiology, and biomedical nformatics. The Director and Co-Directors of the UR CTSI will integrate the clinical and translationalscience functions contained in the CTSB with those functions located at other campus locations, such as functional genomics, other translational resources, and the General Clinical Research Center (GCRC). As an integral part of the CTSI, the GCRCwill move into a newly-renovated 10,500 sq ft facility across the street from the CTSB, with enhanced functionality and subject access. As well, the URCTSI will create two-way synergies with local community groups (school system, faith community, business, foundations) and with other Upstate New York institutions. Further, the UR CTSI will enable the sharing of data across disciplines andacross institutions while assuring the privacy and confidentiality of human subjects. In summary, by coalescing and integrating new facilities with enhanced infrastructure, community and state-widepartnerships, astrong foundation of existing research and training, and a fundamentally reorganizedadministrative structure, the CTSI will transform the conduct of clinical and translational science at UR and contribute nationally to the forging of this new discipline. .

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
Linked Specialized Center Cooperative Agreement (UL1)
Project #
Application #
Study Section
Special Emphasis Panel (ZRR1-CR-3 (01))
Program Officer
Sawczuk, Andrea
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Rochester
Obstetrics & Gynecology
Schools of Dentistry
United States
Zip Code
Justiniano, Carla F; Temple, Larissa K; Swanger, Alex A et al. (2018) Readmissions With Dehydration After Ileostomy Creation: Rethinking Risk Factors. Dis Colon Rectum 61:1297-1305
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Eichinger, Katy; Heatwole, Chad; Iyadurai, Stanley et al. (2018) Facioscapulohumeral muscular dystrophy functional composite outcome measure. Muscle Nerve :
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Akoh, Christine C; Pressman, Eva K; Cooper, Elizabeth et al. (2018) Low Vitamin D is Associated With Infections and Proinflammatory Cytokines During Pregnancy. Reprod Sci 25:414-423
Loelius, Shannon G; Lannan, Katie L; Blumberg, Neil et al. (2018) The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro. Thromb Res 169:96-104
Loelius, Shannon G; Spinelli, Sherry L; Lannan, Katie L et al. (2018) In Vitro Methods to Characterize the Effects of Tobacco and Nontobacco Products on Human Platelet Function. Curr Protoc Toxicol 76:e46
Barrie, Elizabeth S; Pinsonneault, Julia K; Sadee, Wolfgang et al. (2018) Testing genetic modifiers of behavior and response to atomoxetine in autism spectrum disorder with ADHD. J Dev Phys Disabil 30:355-371
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459

Showing the most recent 10 out of 456 publications